Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
September 05, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on...
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
September 03, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially...
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment...
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
– Total Revenue Increased 186% Year-over-Year to $73.8 Million withU.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under...
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. ...
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m....
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk...
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024 07:00 ET
|
Esperion Therapeutics, Inc.
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –...
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024 09:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,...